Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2008

01.01.2008 | Hepatic and Pancreatic Tumors

Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis

verfasst von: Mark B. Slidell, MD, MPH, David C. Chang, MPH, MBA, John L. Cameron, MD, Christopher Wolfgang, MD, PhD, Joseph M. Herman, MD, MSc, Richard D. Schulick, MD, Michael A. Choti, MD, MBA, Timothy M. Pawlik, MD, MPH

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Based on data from other malignancies, the number of lymph nodes evaluated and the ratio of metastatic to examined lymph nodes (LNR) may be important predictors of survival. LNR has never been investigated in a large population-based study of patients with pancreatic adenocarcinoma.

Methods

The Surveillance, Epidemiology, and End Results (SEER) database was used to identify 4005 patients who underwent resection for pancreatic adenocarcinoma from 1988 to 2003. The effect of total lymph node count and LNR on survival was examined using univariate and multivariate analyses.

Results

The median number of lymph nodes examined was seven; 390 (10.1%) patients had no lymph nodes examined. Of those patients who had at least one lymph node examined, 1507 (43.3%) had no lymph node metastases (N0) and 1971 (56.7%) had metastatic nodal disease (N1). Overall median survival was 13 months, and 5-year survival was 6.8%. N1 disease was associated with a worse 5-year survival compared with N0 disease (4.3 vs 11.3%, respectively, P < .001). Patients with N0 disease could be further stratified based on the number of lymph nodes evaluated (median survival: 1–11 nodes, 16 months vs 12 or more nodes, 23 months; P < .001). For N1 patients, LNR was one of the most powerful factors associated with survival (LNR > 0–0.2, 15 months; LNR > 0.2–0.4, 12 months; LNR > 0.4, 10 months) (P < .001).

Conclusions

Most patients have an inadequate number of lymph nodes evaluated following pancreatic surgery. N0 patients who have fewer than 12 lymph nodes examined may be understaged. In patients with N1 disease, LNR may better substratify patients with regard to prognosis.
Literatur
1.
Zurück zum Zitat Greene FL. TNM staging for malignancies of the digestive tract: (2003) changes and beyond. Semin Surg Oncol 2003; 21(1):23–9PubMedCrossRef Greene FL. TNM staging for malignancies of the digestive tract: (2003) changes and beyond. Semin Surg Oncol 2003; 21(1):23–9PubMedCrossRef
2.
Zurück zum Zitat Han SS, Jang JY, Kim SW, et al. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 2006; 32(3):271–5PubMedCrossRef Han SS, Jang JY, Kim SW, et al. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas 2006; 32(3):271–5PubMedCrossRef
3.
Zurück zum Zitat Makary MA, Winter JM, Cameron JL, et al. Pancreaticoduodenectomy in the very elderly. J Gastrointest Surg 2006; 10(3):347–56PubMedCrossRef Makary MA, Winter JM, Cameron JL, et al. Pancreaticoduodenectomy in the very elderly. J Gastrointest Surg 2006; 10(3):347–56PubMedCrossRef
4.
Zurück zum Zitat Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004; 40(4):549–58PubMedCrossRef Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004; 40(4):549–58PubMedCrossRef
5.
Zurück zum Zitat Reber HA. Lymph node involvement as a prognostic factor in pancreatic cancer. Int J Pancreatol 1990; 7(1–3):125–7PubMed Reber HA. Lymph node involvement as a prognostic factor in pancreatic cancer. Int J Pancreatol 1990; 7(1–3):125–7PubMed
6.
Zurück zum Zitat Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8(2):123–32PubMedCrossRef Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001; 8(2):123–32PubMedCrossRef
7.
Zurück zum Zitat Benassai G, Mastrorilli M, Mosella F, Mosella G. Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J Exp Clin Cancer Res 1999; 18(1):23–8PubMed Benassai G, Mastrorilli M, Mosella F, Mosella G. Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. J Exp Clin Cancer Res 1999; 18(1):23–8PubMed
8.
Zurück zum Zitat Gebhardt C, Meyer W, Reichel M, Wunsch PH. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg 2000; 385(1):14–20PubMedCrossRef Gebhardt C, Meyer W, Reichel M, Wunsch PH. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg 2000; 385(1):14–20PubMedCrossRef
9.
Zurück zum Zitat Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237(1):74–85PubMedCrossRef Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237(1):74–85PubMedCrossRef
10.
Zurück zum Zitat Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4(6):567–79PubMedCrossRef Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4(6):567–79PubMedCrossRef
11.
Zurück zum Zitat Pawlik TM, Abdalla EK, Barnett CC, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg 2005; 140(6):584–9; discussion 589–91PubMedCrossRef Pawlik TM, Abdalla EK, Barnett CC, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg 2005; 140(6):584–9; discussion 589–91PubMedCrossRef
12.
Zurück zum Zitat Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997; 226(3):248–7; discussion 257–60PubMedCrossRef Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997; 226(3):248–7; discussion 257–60PubMedCrossRef
13.
Zurück zum Zitat Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21(15):2912–9PubMedCrossRef Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21(15):2912–9PubMedCrossRef
14.
Zurück zum Zitat Tepper JE, O’Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001; 19(1):157–63PubMed Tepper JE, O’Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001; 19(1):157–63PubMed
15.
Zurück zum Zitat Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005; 23(34):8706–12PubMedCrossRef Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005; 23(34):8706–12PubMedCrossRef
16.
Zurück zum Zitat Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002; 9(1):27–34PubMedCrossRef Inoue K, Nakane Y, Iiyama H, et al. The superiority of ratio-based lymph node staging in gastric carcinoma. Ann Surg Oncol 2002; 9(1):27–34PubMedCrossRef
17.
Zurück zum Zitat Bando E, Yonemura Y, Taniguchi K, et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002; 9(8):775–84PubMedCrossRef Bando E, Yonemura Y, Taniguchi K, et al. Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002; 9(8):775–84PubMedCrossRef
18.
Zurück zum Zitat Ichikura T, Ogawa T, Chochi K, et al. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma. World J Surg 2003; 27(3):330–3PubMedCrossRef Ichikura T, Ogawa T, Chochi K, et al. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma. World J Surg 2003; 27(3):330–3PubMedCrossRef
19.
Zurück zum Zitat Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004; 70(3):235–40; discussion 240PubMed Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004; 70(3):235–40; discussion 240PubMed
20.
Zurück zum Zitat Sierzega M, Popiela T, Kulig J, Nowak K. The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas 2006; 33(3):240–5PubMedCrossRef Sierzega M, Popiela T, Kulig J, Nowak K. The ratio of metastatic/resected lymph nodes is an independent prognostic factor in patients with node-positive pancreatic head cancer. Pancreas 2006; 33(3):240–5PubMedCrossRef
21.
Zurück zum Zitat Pawlik TM GA, Cameron JL, Winter JM, et al. Prognostic Relevance of Lymph Node Ratio Following Pancreaticoduodenectomy for Pancreatic Cancer. Surgery 2007; 141(5):610–8PubMedCrossRef Pawlik TM GA, Cameron JL, Winter JM, et al. Prognostic Relevance of Lymph Node Ratio Following Pancreaticoduodenectomy for Pancreatic Cancer. Surgery 2007; 141(5):610–8PubMedCrossRef
22.
Zurück zum Zitat Hartel M, Wente MN, Di Sebastiano P, et al. The role of extended resection in pancreatic adenocarcinoma: is there good evidence-based justification? Pancreatology 2004; 4(6):561–6PubMedCrossRef Hartel M, Wente MN, Di Sebastiano P, et al. The role of extended resection in pancreatic adenocarcinoma: is there good evidence-based justification? Pancreatology 2004; 4(6):561–6PubMedCrossRef
23.
Zurück zum Zitat Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995; 76(11):2343–50PubMedCrossRef Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer 1995; 76(11):2343–50PubMedCrossRef
24.
Zurück zum Zitat Stata Statistical Software: Release 9.2 (computer program). College Station, TX: StataCorp LP 2005 Stata Statistical Software: Release 9.2 (computer program). College Station, TX: StataCorp LP 2005
25.
Zurück zum Zitat Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol 2005; 23(28):7114–24PubMedCrossRef Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol 2005; 23(28):7114–24PubMedCrossRef
26.
Zurück zum Zitat Ludwig MS, Goodman M, Miller DL, Johnstone PA. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest 2005; 128(3):1545–50PubMedCrossRef Ludwig MS, Goodman M, Miller DL, Johnstone PA. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest 2005; 128(3):1545–50PubMedCrossRef
27.
Zurück zum Zitat Liu KJ, Loewen M, Atten MJ, et al. The survival of stage III gastric cancer patients is affected by the number of lymph nodes removed. Surgery 2003; 134(4):639–44; discussion 644–6PubMedCrossRef Liu KJ, Loewen M, Atten MJ, et al. The survival of stage III gastric cancer patients is affected by the number of lymph nodes removed. Surgery 2003; 134(4):639–44; discussion 644–6PubMedCrossRef
28.
Zurück zum Zitat Konety BR, Joslyn SA, O’Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 2003; 169(3):946–50PubMedCrossRef Konety BR, Joslyn SA, O’Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 2003; 169(3):946–50PubMedCrossRef
29.
Zurück zum Zitat Agrama MT, Reiter D, Cunnane MF, et al. Nodal yield in neck dissection and the likelihood of metastases. Otolaryngol Head Neck Surg 2003; 128(2):185–90PubMedCrossRef Agrama MT, Reiter D, Cunnane MF, et al. Nodal yield in neck dissection and the likelihood of metastases. Otolaryngol Head Neck Surg 2003; 128(2):185–90PubMedCrossRef
30.
Zurück zum Zitat Bouvier AM, Haas O, Piard F, et al. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002; 94(11):2862–6PubMedCrossRef Bouvier AM, Haas O, Piard F, et al. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002; 94(11):2862–6PubMedCrossRef
31.
Zurück zum Zitat Wisnivesky JP, Henschke C, McGinn T, Iannuzzi MC. Prognosis of Stage II non-small cell lung cancer according to tumor and nodal status at diagnosis. Lung Cancer 2005; 49(2):181–6PubMedCrossRef Wisnivesky JP, Henschke C, McGinn T, Iannuzzi MC. Prognosis of Stage II non-small cell lung cancer according to tumor and nodal status at diagnosis. Lung Cancer 2005; 49(2):181–6PubMedCrossRef
32.
Zurück zum Zitat Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10(1):65–71PubMedCrossRef Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10(1):65–71PubMedCrossRef
33.
Zurück zum Zitat Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 2006; 13(9):1189–200PubMedCrossRef Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 2006; 13(9):1189–200PubMedCrossRef
34.
Zurück zum Zitat Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003; 169(3):943–5PubMedCrossRef Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003; 169(3):943–5PubMedCrossRef
35.
Zurück zum Zitat Thorn CC, Woodcock NP, Scott N, et al. What factors affect lymph node yield in surgery for rectal cancer? Colorectal Dis 2004; 6(5):356–61PubMedCrossRef Thorn CC, Woodcock NP, Scott N, et al. What factors affect lymph node yield in surgery for rectal cancer? Colorectal Dis 2004; 6(5):356–61PubMedCrossRef
Metadaten
Titel
Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis
verfasst von
Mark B. Slidell, MD, MPH
David C. Chang, MPH, MBA
John L. Cameron, MD
Christopher Wolfgang, MD, PhD
Joseph M. Herman, MD, MSc
Richard D. Schulick, MD
Michael A. Choti, MD, MBA
Timothy M. Pawlik, MD, MPH
Publikationsdatum
01.01.2008
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2008
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9587-1

Weitere Artikel der Ausgabe 1/2008

Annals of Surgical Oncology 1/2008 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.